Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-10-28 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 6250 | $28.49 - $29.11 | $178,484 |
| 2024-10-28 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 6250 | $2.48 - $2.48 | $15,500 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 716 | $30.00 - $30.00 | $21,482 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 847 | $30.00 - $30.00 | $25,412 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 924 | $30.00 - $30.00 | $27,722 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 814 | $30.00 - $30.00 | $24,422 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 814 | $2.48 - $2.48 | $2,018 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1570 | $30.00 - $30.00 | $47,103 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Collins Helen Louise
(CHIEF MEDICAL OFFICER) |
S | Common Stock | D | 816 | $30.00 - $30.00 | $24,482 |
| 2024-10-18 | Enliven Therapeutics, Inc. | Collins Helen Louise
(CHIEF MEDICAL OFFICER) |
M | Common Stock | A | 816 | $2.48 - $2.48 | $2,023 |
| 2024-10-15 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $27.67 - $27.67 | $35,143 |
| 2024-10-08 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 51145 | $27.96 - $28.52 | $1,437,584 |
| 2024-10-08 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 29977 | $27.95 - $28.53 | $841,333 |
| 2024-10-08 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
S | Common Stock | D | 10420 | $28.17 - $28.17 | $293,557 |
| 2024-10-08 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
M | Common Stock | A | 10420 | $5.52 - $19.68 | $146,924 |
| 2024-10-04 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 10229 | $27.51 - $27.61 | $281,663 |
| 2024-10-04 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 14936 | $27.50 - $27.51 | $410,866 |
| 2024-10-04 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 11488 | $27.51 - $27.51 | $316,013 |
| 2024-10-04 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 11488 | $2.48 - $2.48 | $28,489 |
| 2024-10-04 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 2825 | $27.51 - $27.51 | $77,703 |
| 2024-10-01 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 527 | $27.54 - $27.54 | $14,512 |
| 2024-10-01 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 526 | $27.54 - $27.54 | $14,484 |
| 2024-10-01 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 521 | $27.54 - $27.54 | $14,346 |
| 2024-10-01 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 521 | $2.48 - $2.48 | $1,292 |
| 2024-10-01 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 518 | $27.54 - $27.54 | $14,264 |
| 2024-09-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 6250 | $24.27 - $25.33 | $153,828 |
| 2024-09-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 6250 | $2.48 - $2.48 | $15,500 |
| 2024-09-16 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $22.41 - $22.41 | $28,458 |
| 2024-08-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 4250 | $22.54 - $22.54 | $95,781 |
| 2024-08-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 4250 | $2.48 - $2.48 | $10,540 |
| 2024-08-26 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $22.89 - $22.89 | $274,718 |
| 2024-08-15 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $22.82 - $23.70 | $29,525 |
| 2024-07-31 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 3099 | $27.56 - $27.56 | $85,399 |
| 2024-07-31 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 2270 | $27.56 - $27.56 | $62,555 |
| 2024-07-31 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 991 | $27.53 - $27.53 | $27,280 |
| 2024-07-31 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 991 | $2.48 - $2.48 | $2,457 |
| 2024-07-31 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 2351 | $27.50 - $27.51 | $64,662 |
| 2024-07-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 12000 | $26.69 - $27.43 | $320,376 |
| 2024-07-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 5250 | $26.67 - $27.44 | $140,052 |
| 2024-07-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 5250 | $2.48 - $2.48 | $13,020 |
| 2024-07-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $24.53 - $25.83 | $299,071 |
| 2024-07-15 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $24.80 - $24.80 | $31,496 |
| 2024-07-12 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 50000 | $25.01 - $25.07 | $1,252,825 |
| 2024-07-12 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 3000 | $25.07 - $25.07 | $75,195 |
| 2024-07-12 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 3000 | $2.48 - $2.48 | $7,440 |
| 2024-06-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 4250 | $21.79 - $23.43 | $95,921 |
| 2024-06-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 4250 | $2.48 - $2.48 | $10,540 |
| 2024-06-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $21.63 - $22.30 | $259,901 |
| 2024-06-17 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $21.48 - $21.48 | $27,277 |
| 2024-06-06 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 1133 | $20.06 - $20.06 | $22,722 |
| 2024-06-06 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
M | Common Stock | A | 1133 | $2.48 - $2.48 | $2,809 |
| 2024-05-28 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $22.86 - $24.34 | $278,209 |
| 2024-05-28 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-05-28 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 4250 | $22.89 - $24.34 | $98,529 |
| 2024-05-28 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 4250 | $2.48 - $2.48 | $10,540 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |